The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated×5•Originally published 20 April 2026•Updated 21 April 2026•

1 min read

Eli Lilly Upgraded to Buy While Novartis Outlook Weakens on Drug Sales Slump

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Eli Lilly was upgraded from Sell to Buy following a 13% price pullback and strong Q4 guidance.

2The company targets 25% topline growth by 2026, driven by the weight loss franchise which accounts for 56% of revenue.

about 1 month ago

Version History

Version 5about 1 month ago

What changed: Updated the story to include recent trading data showing declines in Eli Lilly, Hims & Hers, SoundHound AI, and Alibaba, while noting the gain in Nextracker.

Version 4about 1 month ago

What changed: The story was updated to include Novartis's rating downgrade driven by a significant sales slump in its key drug Entresto and a correction from its 52-week high.

Version 3about 1 month ago

What changed: Added new investment details regarding Lumentum Holdings (LITE), focusing on its transition to an optical platform provider and its attractive forward PEG ratio relative to the sector.

Version 2about 1 month ago

What changed: The story was updated to include assertions from Seeking Alpha analysts that the stock has not yet reached its peak valuation, reinforcing the bullish outlook.

Version 1about 1 month ago

What changed: The story was updated to highlight how Eli Lilly is specifically deploying capital generated from its GLP-1 franchise to fund strategic investments and biotech expansions.

Market dynamics showed a broad pullback across multiple sectors, with Eli Lilly (LLY) shares declining 1.83% to close at $903.02 despite its recent upgrade to 'Buy' based on 2026 growth targets. In the digital healthcare space, Hims & Hers Health (HIMS) dropped 4.03% to $29.76, while Novartis (NVS) remains under pressure from weakening sales of its drug Entresto. The downward trend extended to the AI sector as SoundHound AI (SOUN) fell 5.65%, and e-commerce giant Alibaba (BABA) declined 3.42% to close at $135.38. Conversely, Nextracker (NXT) demonstrated resilience against the general market decline, advancing 1.46% to reach $108.05. These developments highlight a cautious market sentiment as investors recalibrate positions across healthcare, technology, and growth stocks.